CinCor Pharma to Participate at Upcoming September Investor Conferences
August 31, 2022 08:00 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th...
CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress
August 22, 2022 08:00 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a...
CinCor Pharma Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
August 15, 2022 16:17 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate,...
CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
August 11, 2022 00:38 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate,...
CinCor Pharma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
August 08, 2022 17:34 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate,...
CinCor Reports Second Quarter Financial Results and Provides Corporate Update
August 08, 2022 07:15 ET
|
CinCor Pharma, Inc.
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension ...
CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension
August 08, 2022 07:00 ET
|
CinCor Pharma, Inc.
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis,...
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
July 26, 2022 08:00 ET
|
CinCor Pharma, Inc.
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected in 2H 2022 Topline Data for Phase 2 BrigHtn Trial Expected in August 2022 ...
CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease
June 01, 2022 08:00 ET
|
CinCor Pharma, Inc.
figHTN-CKD is CinCor’s fourth ongoing Phase 2 clinical trial evaluating baxdrostat (CIN-107) Initial topline data for figHTN-CKD expected in 2H 2023 WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE)...
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
December 09, 2021 08:00 ET
|
CinCor Pharma, Inc.
CINCINNATI, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective,...